ATE406360T1 - Antagonisten der opioidrezeptoren - Google Patents
Antagonisten der opioidrezeptorenInfo
- Publication number
- ATE406360T1 ATE406360T1 AT04716082T AT04716082T ATE406360T1 AT E406360 T1 ATE406360 T1 AT E406360T1 AT 04716082 T AT04716082 T AT 04716082T AT 04716082 T AT04716082 T AT 04716082T AT E406360 T1 ATE406360 T1 AT E406360T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonists
- opioid receptors
- racemate
- diastereomer
- enantiomer
- Prior art date
Links
- 102000003840 Opioid Receptors Human genes 0.000 title 1
- 108090000137 Opioid Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45324303P | 2003-03-07 | 2003-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406360T1 true ATE406360T1 (de) | 2008-09-15 |
Family
ID=32990743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04716082T ATE406360T1 (de) | 2003-03-07 | 2004-03-01 | Antagonisten der opioidrezeptoren |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7396943B2 (de) |
| EP (1) | EP1606275B1 (de) |
| JP (1) | JP2006519855A (de) |
| CN (1) | CN1753884A (de) |
| AT (1) | ATE406360T1 (de) |
| AU (1) | AU2004220113A1 (de) |
| BR (1) | BRPI0408108A (de) |
| CA (1) | CA2513791A1 (de) |
| DE (1) | DE602004016127D1 (de) |
| ES (1) | ES2312972T3 (de) |
| MX (1) | MXPA05009367A (de) |
| WO (1) | WO2004080996A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| ES2392200T3 (es) * | 2002-09-19 | 2012-12-05 | Eli Lilly & Company | Ésteres de diarilo como antagonistas del receptor opiáceo |
| ES2528631T3 (es) | 2003-04-08 | 2015-02-11 | Progenics Pharmaceuticals, Inc. | Formulaciones farmacéuticas que contienen metilnaltrexona |
| JP2006522824A (ja) * | 2003-04-09 | 2006-10-05 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症性疾患を処置するために有用なβ−カルボリン |
| BRPI0417156A (pt) | 2003-12-12 | 2007-03-06 | Lilly Co Eli | composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso |
| JP2007516284A (ja) * | 2003-12-22 | 2007-06-21 | イーライ リリー アンド カンパニー | オピオイド受容体拮抗物質 |
| GB0402137D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402140D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| ATE399164T1 (de) | 2004-03-12 | 2008-07-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| DE602005022572D1 (de) | 2004-03-12 | 2010-09-09 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| ES2318472T3 (es) | 2004-03-15 | 2009-05-01 | Eli Lilly And Company | Derivados de 5-(5-(aminoetil)-indol-1-ilmetil)-benzamida y compuestos relacionados como antagonistas del receptor opioide para el tratamiento de la obesidad. |
| EP1735268B1 (de) | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Antagonisten des opioidrezeptors |
| EP1856053A1 (de) | 2005-01-14 | 2007-11-21 | Millennium Pharmaceuticals, Inc. | Cinnamid- und hydrocinnamid-derivate mit raf-kinase hemmender aktivität |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| CN101171010B (zh) * | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| JP4887368B2 (ja) | 2005-10-13 | 2012-02-29 | スミスクライン ビーチャム コーポレーション | 新規ヘテロ環化合物 |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| KR20090051778A (ko) | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
| MX2009010550A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas. |
| PT2139890E (pt) | 2007-03-29 | 2014-09-03 | Wyeth Llc | Antagonistas do receptor opióide periférico e respectivas utilizações |
| PA8774201A1 (es) | 2007-03-29 | 2009-06-23 | Progenics Pharm Inc | Antagonista del receptor |
| WO2008142454A1 (en) | 2007-05-22 | 2008-11-27 | Prosidion Limited | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders |
| US8063247B2 (en) | 2007-09-07 | 2011-11-22 | Prosidion Limited | Bicyclic aryl and heteroaryl receptor modulators |
| CN101925576B (zh) * | 2008-01-22 | 2013-02-06 | 伊莱利利公司 | κ-选择性阿片受体拮抗剂 |
| CN101959892B (zh) | 2008-02-06 | 2014-01-08 | 普罗热尼奇制药公司 | (r),(r)-2,2’-二-甲基纳曲酮的制备和用途 |
| US8685995B2 (en) | 2008-03-21 | 2014-04-01 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| WO2010096790A1 (en) * | 2009-02-23 | 2010-08-26 | Mallinckrodt Inc. | (+)-morphinananium n-oxides and processes for their production |
| KR20120092592A (ko) * | 2009-09-18 | 2012-08-21 | 아돌로 코포레이션 | 위장관 질환을 위한 오피오이드 수용체 길항제의 용도 |
| US9751847B2 (en) | 2010-10-14 | 2017-09-05 | University Of Utah Research Foundation | Methods and compositions related to neuroactive thiazoline compounds |
| CN106117195A (zh) * | 2016-06-09 | 2016-11-16 | 青岛辰达生物科技有限公司 | 一种用于治疗白血病的药物达沙替尼的合成方法 |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| CN112341404B (zh) * | 2019-08-09 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 噻唑类衍生物或盐、异构体、其制备方法及用途 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| AU2022418436A1 (en) | 2021-12-20 | 2024-07-11 | Nimml Institute | Immunoregulatory compounds |
| JP2025508051A (ja) | 2022-03-07 | 2025-03-21 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 大うつ病性障害の治療に使用するためのアチカプラントの多形形態 |
| EP4489730A1 (de) | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Zusammensetzungen mit atikaprant |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4891379A (en) * | 1987-04-16 | 1990-01-02 | Kabushiki Kaisha Kobe Seikosho | Piperidine opioid antagonists |
| AUPP796798A0 (en) * | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| DK1347971T3 (da) * | 2000-12-21 | 2006-05-15 | Bristol Myers Squibb Co | Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien |
| KR100894189B1 (ko) | 2001-03-29 | 2009-04-22 | 일라이 릴리 앤드 캄파니 | 5-ｈｔ6 수용체의 길항제로서의 ｎ-(2-아릴에틸)벤질아민 |
-
2004
- 2004-03-01 DE DE602004016127T patent/DE602004016127D1/de not_active Expired - Lifetime
- 2004-03-01 CA CA002513791A patent/CA2513791A1/en not_active Abandoned
- 2004-03-01 US US10/544,286 patent/US7396943B2/en not_active Expired - Fee Related
- 2004-03-01 CN CNA2004800050293A patent/CN1753884A/zh active Pending
- 2004-03-01 AU AU2004220113A patent/AU2004220113A1/en not_active Abandoned
- 2004-03-01 MX MXPA05009367A patent/MXPA05009367A/es unknown
- 2004-03-01 ES ES04716082T patent/ES2312972T3/es not_active Expired - Lifetime
- 2004-03-01 JP JP2006508678A patent/JP2006519855A/ja not_active Withdrawn
- 2004-03-01 WO PCT/US2004/003368 patent/WO2004080996A1/en not_active Ceased
- 2004-03-01 AT AT04716082T patent/ATE406360T1/de not_active IP Right Cessation
- 2004-03-01 BR BRPI0408108-0A patent/BRPI0408108A/pt not_active Application Discontinuation
- 2004-03-01 EP EP04716082A patent/EP1606275B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004080996A1 (en) | 2004-09-23 |
| DE602004016127D1 (de) | 2008-10-09 |
| CN1753884A (zh) | 2006-03-29 |
| EP1606275A1 (de) | 2005-12-21 |
| US20060166987A1 (en) | 2006-07-27 |
| JP2006519855A (ja) | 2006-08-31 |
| ES2312972T3 (es) | 2009-03-01 |
| US7396943B2 (en) | 2008-07-08 |
| CA2513791A1 (en) | 2004-09-23 |
| EP1606275B1 (de) | 2008-08-27 |
| AU2004220113A1 (en) | 2004-09-23 |
| MXPA05009367A (es) | 2005-11-04 |
| BRPI0408108A (pt) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE406360T1 (de) | Antagonisten der opioidrezeptoren | |
| ATE377589T1 (de) | 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten | |
| DE60302157D1 (de) | Opioidrezeptorantagonisten | |
| HRP20050253B1 (hr) | Diaril eteri kao opioid antagonisti opioidnih receptora | |
| CO5680444A2 (es) | Agonista a-2 no sedante 1-(2,3-dimetil-fenil)-etil-1,3-dihidro-imidazol-2-tiona | |
| TW200714583A (en) | Substituted gamma lactams as therapeutic agents | |
| CY1108378T1 (el) | 4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu | |
| ATE545413T1 (de) | Antagonisten des opioidrezeptors | |
| NO20041504L (no) | Lactamderivater som antagonister for humane 11CBY reseptorer. | |
| HRP20090281T1 (hr) | 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti | |
| MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
| WO2004000808A3 (en) | N-substituted piperidine derivatives as serotonin receptor agents | |
| WO2008005368A3 (en) | Piperazines as p2x7 antagonists | |
| BRPI0512516A (pt) | composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
| MXPA05013474A (es) | Derivados de quinolilamida como antagonistas de ccr-5. | |
| EA200400467A1 (ru) | Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора | |
| WO2004082623A3 (en) | Substituted piperidine compounds | |
| ATE399770T1 (de) | Tachykininrezeptorantagonisten | |
| DE602004009200D1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| ATE475640T1 (de) | Antagonisten des opioidrezeptors | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| EP1617806A4 (de) | Selektive spirocyclische glucocorticoid-rezeptor-modulatoren | |
| WO2004067703A3 (en) | 5ht7 antagonists and inverse agonists | |
| WO2004111008A3 (en) | Use of a compound of formula i for making a pharmaceutical composition | |
| DK1814848T3 (da) | 2,3,4-substitueret-cyclopentanoner som terapeutiske midler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |